https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983491/Interesting...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983491/

Interesting that it cites Eric Strati as one of the authors, whom was head of commercial at MSB.
I'm guessing he engaged the consultants noted and worked with them to get this produced and published.
He was named in the 2020 end of year report as Senior Management personnel, but seems to have left Mesoblast in June 2021. I recall some discussion on this here at the time but cant seem to find it. Interestingly, if you check on the MSB website, the management page seems to be updated but has no replacement for Head of Commercial. I wonder why.

Also noticed that the 2020 reporting lists John McMannis as head of manufacturing. He worked for Mesoblast since 2011 but left in November 2020, a very short time after the CRL was issued. Interesting.
He now works for Cellenkos which is an early stage cell therapy platform. Not listed on their website as key management. Doesn't seem like a move up for him. Would be quite easy to conclude he was pushed out.